Second, the selection of TP53 mutant clones confers a high risk of developing secondary myeloid malignancies, including AML as seen in PD37580, whose disease was treatment-refractory and carried biallelic TP53 mutations and a complex karyotype. Here, TP53 is linked to acute myeloid leukemia.